BRAIN and NERVE－神経研究の進歩76巻5号

2024年05月発行

増大特集 末梢神経・筋肉の自己免疫性・炎症性疾患ハンドブック

第2章　疾患各論

AChR抗体陽性重症筋無力症

著者： 村井弘之¹

所属機関： ¹国際医療福祉大学医学部脳神経内科学

ページ範囲：P.613 - P.620

文献概要

アセチルコリン受容体（acetylcholine receptor：AChR）抗体陽性重症筋無力症の病態，診断，治療についてまとめた。その発症機序の上流部分には，AChRに感作されたT細胞依存性にB細胞から自己抗体が産生されるという過程がある。下流部分では，産生されたAChR抗体が補体系を活性化させ，運動終板を破壊する。治療の目標は患者の生活の質を担保することである。新しく登場してきた分子標的薬についても紹介する。

参考文献

1）Yoshikawa H, Adachi Y, Nakamura Y, Kuriyama N, Murai H, et al; Taskforce of Validation of Evidence-based Diagnosis and Guidelines, and Impact on Quality of Life (QOL) in Patients with Neuroimmunological Diseases: Two-step nationwide epidemiological survey of myasthenia gravis in Japan 2018. PLOS One 17: e0274161, 2022［doi: 10.1371/journal.pone.0274161］

2）Murai H, Yamashita N, Watanabe M, Nomura Y, Motomura M, et al: Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey. J Neurol Sci 305: 97-102, 2011

3）Somnier FE: Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis. Neurology 65: 928-930, 2005

4）Conti-Fine BM, Milani M, Kaminski HJ: Myasthenia gravis: past, present, and future. J Clin Invest 116: 2843-2854, 2006

5）Higuchi O, Hamuro J, Motomura M, Yamanashi Y: Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 69: 418-422, 2011

6）日本神経学会（監修）, 重症筋無力症／ランバート・イートン筋無力症候群診療ガイドライン作成委員会（編）: 重症筋無力症／ランバート・イートン筋無力症候群診療ガイドライン2022. 南江堂, 東京, 2022

7）Imai T, Utsugisawa K, Murai H, Tsuda E, Nagane Y, et al: Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan. J Neurol Neurosurg Psychiatry 89: 513-517, 2018

8）Imai T, Suzuki S, Tsuda E, Nagane Y, Murai H, et al: Oral corticosteroid therapy and present disease status in myasthenia gravis. Muscle Nerve 51: 692-696, 2015

9）Uzawa A, Suzuki S, Kuwabara S, Akamine H, Onishi Y, et al: Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry 94: 467-473, 2023

10）Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, et al; MGTX Study Group: Randomized trial of thymectomy in myasthenia gravis. N Engl J Med 375: 511-522, 2016

11）Kooshesh KA, Foy BH, Sykes DB, Gustafsson K, Scadden DT: Health consequences of thymus removal in adults. N Engl J Med 389: 406-417, 2023

12）Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, et al; REGAIN Study Group: Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16: 976-986, 2017

13）Vu T, Ortiz S, Katsuno M, Annane D, Mantegazza R, et al: Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis. J Neurol 270: 3129-3137, 2023

14）Howard JF Jr, Bresch S, Genge A, Hewamadduma C, Hinton J, et al; RAISE Study Team: Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol 22: 395-406, 2023

15）Howard JF Jr, Bril V, Vu T, Karam C, Peric S, et al; ADAPT Investigator Study Group: Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20: 526-536, 2021

16）Hehir MK, Hobson-Webb LD, Benatar M, Barnett C, Silvestri NJ, et al: Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review. Neurology 89: 1069-1077, 2017